...
首页> 外文期刊>MBio >Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
【24h】

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”

机译:回复Das和Berkhout,“ HIV-1 RNA基因组中的多嘌呤区变化如何引起对整合酶抑制剂Dolutegravir的耐​​药性”

获取原文
   

获取外文期刊封面封底 >>

       

摘要

REPLY Strand transfer inhibitors are potent molecules targeting HIV-1 integration, a critical step involved in retroviral replication. To date, three inhibitors, raltegravir, elvitegravir, and dolutegravir (DTG), are available to treat infected patients. Unfortunately, many resistance pathways have been described for raltegravir and elvitegravir, and all mutations leading to strand transfer resistance have been located in the integrase gene. In the case of dolutegravir, the last integrase inhibitor, only a few mutations described from patients or from in vitro selection are reported to confer resistance ( 1 – 3 ). Following the publication of the article describing a virus having selected mutations outside the integrase gene and conferring resistance to HIV-1 integrase inhibitors ( 4 ), Das and Berkhout propose a model for the replication of this 3′-polypurine-tract (3′-PPT)-mutated virus ( 18 ). Integration of the viral DNA would be possible due to the modification of the 5′ long terminal repeat (LTR) end which makes the virus insensitive to dolutegravir action, allowing it to integrate into the host genome. This hypothesis is plausible since an optimal binding of dolutegravir on the integrase/DNA complex is required for inhibition of the compound and the binding requires the canonical LTR end ( 5 ). Since integration is a concerted mechanism occurring in the intasome composed of integrase and both LTR ends, the deficient binding of dolutegravir on the 5′ LTR could allow the unmodified 3′ LTR end to become insensitive to dolutegravir. Indeed, as reported in the literature, mutations at one end could have consequences for the other end ( 6 ). Consequently, integration of both 5′ LTR and 3′ LTR could occur despite lower efficiency, explaining the resistance of the 3′-PPT mutant to dolutegravir. Since 2-LTR circles are formed by ligation of the two LTR ends by the nonhomologous end joining (NHEJ) pathway, the LTR-LTR junction should reflect the integrity of the LTR ends ( 7 ). To test this hypothesis, sequencing of the U3-U5 junction of 2-LTR circles was carried out from MT-4 cells infected with the wild-type (WT) and 3′-PPT-mutated viruses with or without DTG (without DTG at day 6 for WT and day 8 for mutated virus and with DTG at day 15 for 3′-PPT-mutated virus). Briefly, after extraction of DNA, a fragment of 307 nucleotides encompassing more than 100 nucleotides from either side of the junction was amplified using primers specific for U3 and U5 sequences, and pyrosequencing on a GS Junior sequencer (Roche 454 Life Sciences) was performed. A total of 1,675 and 1,280 reads per nucleotide position was amplified for WT and mutant viruses, respectively. Interestingly, we found that the LTR-LTR junction was identical to the palindromic sequence found by the predicted ligation of the two unprocessed DNA ends with a total similitude between the two analyzed viruses. Sequence analysis, as described in the literature ( 17 ), showed that around 50% (53.7% for WT and 50% for the mutant) of circle junctions were similar to the expected sequence and that the remaining 50% of sequences had multiple deletions ranging from 1 to several tens of nucleotides, located on either side of the junction (U5 or U3) or extending over the U5-U3 junction. These data show that no additional bases were detected in the 3′ PPT compared to the WT virus, highlighting the classical DNA ends of the 2-LTR WT virus. These data sustain the idea that the reverse transcription step does not lead to a modification of LTR ends during the replication of the 3′-PPT-mutated virus ( Fig. 1 ). FIG?1? Comparison between the classical HIV-1 replication cycle and the proposed alternative replication cycle of the 3′-PPT mutant. (Left) The classical HIV-1 replication cycle leading to the integration of viral DNA at the level of genomic DNA. (Right) The proposed alternative replication cycle leading mainly to the formation of 1-LTR circles during the reverse transcription steps. The CAGT sequence inside the mutated 3′ PPT, upstream of U3, could be an enhancer of transcription initiation, allowing viral production from 1-LTR circles and explaining the resistance to DTG. We agree with Das and Berkhout in suggesting that the mutation in the 3′ PPT leads to a modification of the reverse transcription, but instead of modifying LTR ends, we predict for ourselves that the presence of the mutation, disrupting the 3′ PPT, would lead to a total degradation of the RNA by the RNase H activity and an impairment of the synthesis of the U3-R-U5-PBS (primer binding site) +DNA from the 3′ PPT ( Fig. 2 ). The initiation of the +DNA could be then started from sequences located upstream of the 3′ PPT as reported in the literature ( 8 ). We can speculate, in this case, that synthesis of a longer +DNA fragment could prevent the translocation of the DNA that would lead to an intramolecular circularization of the viral genome using the complementary PBS regions. After circularizatio
机译:回复链转移抑制剂是靶向HIV-1整合的有效分子,这是逆转录病毒复制中的关键步骤。迄今为止,可以使用三种抑制剂raltegravir,elvitegravir和dolutegravir(DTG)治疗感染的患者。不幸的是,已经描述了raltegravir和elvitegravir的许多抗性途径,所有导致链转移抗性的突变都位于整合酶基因中。就最后一种整合酶抑制剂dolutegravir而言,据报道仅从患者或体外选择中描述的少数突变具有耐药性(1-3)。文章发表后描述了一种病毒,该病毒在整合酶基因之外具有选定的突变,并赋予了对HIV-1整合酶抑制剂的抗性(4),Das和Berkhout提出了一种用于复制该3'-多嘌呤片段(3'- PPT)突变病毒(18)。由于5'长末端重复序列(LTR)末端的修饰,病毒DNA的整合将是可能的,这使病毒对dolutegravir的作用不敏感,使其能够整合到宿主基因组中。该假设是合理的,因为抑制化合物需要dolutegravir在整合酶/ DNA复合物上的最佳结合才能抑制该化合物,而结合则需要规范的LTR末端(5)。由于整合是在整合酶和两个LTR末端组成的整合体中发生的协调机制,因此dolutegravir在5'LTR上的结合不足会使未修饰的3'LTR末端对dolutegravir不敏感。实际上,正如文献报道的那样,一端的突变可能会对另一端产生影响(6)。因此,尽管效率较低,但仍可能发生5'LTR和3'LTR的整合,解释了3'-PPT突变体对dolutegravir的抗性。由于2-LTR环是通过非同源末端连接(NHEJ)途径连接两个LTR末端而形成的,因此LTR-LTR连接应反映LTR末端的完整性(7)。为了验证这一假设,对感染了野生型(WT)和3'-PPT突变病毒且有或没有DTG的MT-4细胞中2-LTR环的U3-U5连接进行测序第6天是WT,第8天是突变病毒,第15天是DTG(3'-PPT突变病毒)。简而言之,在提取DNA之后,使用对U3和U5序列具有特异性的引物扩增从连接的任一侧起包含100个以上核苷酸的307个核苷酸的片段,并在GS Junior测序仪(Roche 454 Life Sciences)上进行焦磷酸测序。对于野生型和突变型病毒,每个核苷酸位置总共扩增了1,675和1,280个读数。有趣的是,我们发现LTR-LTR连接与回文序列完全相同,回文序列是通过两个未加工的DNA末端的预测连接发现的,并且在两个分析的病毒之间具有总的相似性。如文献(17)所述,序列分析显示大约50%的环状连接(WT为53.7%,突变体为50%)与预期序列相似,其余50%的序列具有多个缺失范围1至数十个核苷酸,位于连接处(U5或U3)的任一侧或在U5-U3连接处延伸。这些数据表明,与WT病毒相比,在3'PPT中未检测到其他碱基,突出了2-LTR WT病毒的经典DNA末端。这些数据支持了逆转录步骤不会导致3'-PPT突变病毒复制过程中LTR末端修饰的想法(图1)。图。1?比较经典的HIV-1复制周期和3'-PPT突变体的拟议替代复制周期。 (左)经典的HIV-1复制周期导致病毒DNA在基因组DNA水平上整合。 (右)拟议的替代复制周期主要导致在逆转录步骤中形成1-LTR环。在U3上游的突变3'PPT内部的CAGT序列可能是转录起始的增强子,允许从1-LTR环产生病毒并解释了对DTG的抗性。我们同意Das和Berkhout的观点,认为3'PPT中的突变会导致逆转录的修饰,但我们自己预测突变的存在会破坏3'PPT,而不是修饰LTR末端,而不是修饰LTR末端。通过RNA酶H活性导致RNA的总降解,以及从3′PPT(图2)合成U3-R-U5-PBS(引物结合位点)+ DNA的合成受到损害。如文献报道(8),然后可以从位于3'PPT上游的序列开始+ DNA的起始。在这种情况下,我们可以推测,更长的+ DNA片段的合成可以防止DNA的移位,从而导致使用互补PBS区进行病毒基因组的分子内环化。循环化后

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号